Gilead Sciences Renews WHO Collaboration to Help Treat Visceral Leishmaniasis
MT Newswires Live
May 21
Gilead Sciences (GILD) and the World Health Organization expanded a five-year partnership to help eliminate visceral leishmaniasis, a potentially fatal parasitic disease, Gilead Sciences said Thursday.
Under the agreement, Gilead will provide more than 400,000 vials of AmBisome and $9.2 million in funding through 2030 to support diagnosis and treatment efforts in high-burden countries, particularly in East Africa.
The company said the partnership has already helped reduce new visceral leishmaniasis cases in Southeast Asia by more than 95% since 2005, with Bangladesh achieving elimination status as a public health problem in 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.